gpr40 agonist

Vincamine (Perval) is a major alkaloid of Vinca minor L., Apocynaceae. It has been used therapeutically as a vasodilator and antihypertensive agent, particularly in cerebrovascular disorders.

GPR40 Agonist 2 is a compound that functions as a GPR40 agonist and is utilized in diabetes research.

GPR40 agonist 1 is an effective new GPR40 agonist (EC50s: 17 nM and 2 nM for rGPR40 and hGPR40).

GPR40 agonist 8 (Compound 2) is a GPR40 agonist with an EC50 value of 5 nM for hGPR40Ca2+. It is applicable in research related to type II diabetes and obesity.

GPR40 agonist 6 (Compound 7a) is a potent and selective agonist of free fatty acid receptor 1 (FFAR1 or GPR40) with an EC50 of 0.058 μM against GPR40 [1].

GPR40 agonist 5 is an orally active GPR40 (G protein-coupled receptor 40) agonist (EC50: 47 nM). gPR40 agonist 5 reduces blood glucose levels and improves glucose tolerance. gPR40 agonist 5 shows adequate control of hyperglycemic state in type 2 diabetic mice.

Compound 1, also known as GPR40 agonist 7, is an orally active agonist of the G protein-coupled receptor 40 (GPR40). It effectively enhances the secretion of insulin and GLP-1, exhibiting a hypoglycemic effect in vivo with an ED 50 of 0.58 mg/kg [1].

Fezagepras sodium (Setogepram sodium salt) is an orally active GPR40 agonist and is an antagonist or inverse agonist for GPR84, with anti-fibrotic, anti-inflammatory and anti-proliferative actions.

MEDICA16 is a selective agonist for GPR40 as well as a partial agonist for GPR120. MEDICA16, an ATP-citrate lyase inhibitor, significantly reduces intracellular TG content in gastrocnemius muscle with an increase in insulin sensitivity.

LY2881835 is a potent and selective GPR40 agonist.

AM-4668, a GPR40 (FFA1) agonist with oral availability, was optimized to reduce central nervous system (CNS) permeability, with a mouse brain/plasma ratio of only 0.02, and significantly reduced blood glucose levels in human GPR40 knock-in mice.

GPR40/FFAR1 modulator 1 is a Gq-coupled free fatty acid receptor 1 (GPR40/FFAR1) agonist and allosteric modulator.

HWL-088 is a potent free fatty acid receptor 1 (FFA1/GPR40) agonist. HWL-088 significantly improves glucose tolerance in normal and diabetic models.

Fezagepras (Setogepram) is an orally active GPR40 agonist and is an antagonist or inverse agonist of GPR84 with anti-inflammatory, anti-fibrotic, and anti-proliferative actions.

AP5 is a potent and selective agonist for the GPR40 receptor with positive allosteric modulation of endogenous ligands (AgoPAM). AP5 demonstrates a rat hIP1 EC50 of 0.49 nM against the GPR40 receptor.

AM-1638 is an orally active GPR40/FFA1 agonist, useful for studying type II diabetes.

AMG 837 sodium salt is a potent GPR40 agonist(EC50=13 nM) with a superior pharmacokinetic profile and robust glucose-dependent stimulation of insulin secretion in rodents. IC50 value: 13 nM (EC50) [1] Target: GPR40 agonist AMG 837 displayed the expected t

AMG 837 is a novel and potent GPR40/FFA1 agonist that enhances insulin secretion and lowers blood glucose levels in rodents.

LY2922470 reduces glucose levels along with significant enhancements in insulin and GLP-1, which is the potential for the treatment of type 2 diabetes mellitus (T2DM). LY2922470 is an effective, selective, and orally available agonist of the G protein-cou

TUG-424 significantly enhances glucose-stimulated insulin secretion at 100 nM. TUG-424 is a potent and selective free fatty acid receptor 1 agonist (EC50: 32 nM).

GW9508(GW 9508) is a potent and selective agonist for FFA1 (GPR40), stimulates insulin secretion in a glucose-sensitive manner.

K-757 is a GPR40 agonist with an EC50 value of 2.1 ± 0.2 nM for human GPR40. In preclinical species, K-757 has a half-life ranging from 1 to 11 hours. It can stimulate the secretion of GLP-1 and shows potential applications in weight loss studies.

Fasiglifam (TAK875) is a potent, selective and orally bioavailable GPR40 agonist.

TAK-875 Hemihydrate (Fasiglifam) is a selective GPR40 agonist with EC50 of 14 nM, 400-fold more potent than oleic acid.